GleamWall
中文EN

EXOZ EXOZYMES INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2010788 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-21.6%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-268.1%
ROA-149.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-41.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$3.71M$1.87M
SG&A expense$6.01M$4.06M
Operating income-$9.72M-$5.93M
Pretax income-$9.26M-$5.86M
Income tax-$105,205—
Net income-$9.16M-$5.86M
EBITDA-$9.43M-$5.66M
EPS (basic)-1.09-0.89
EPS (diluted)-1.09-0.89
Weighted avg. shares (diluted)8.38M6.56M
Balance sheet
Cash & equivalents$3.04M$9.72M
Current assets$3.94M$10.82M
PP&E, net$764,401$882,445
Total assets$5.97M$13.03M
Current liabilities$1.57M$1.33M
Total liabilities$2.57M$2.61M
Shareholders' equity$3.40M$10.42M
Shares outstanding8.41M8.37M
Cash flow statement
Operating cash flow-$6.50M-$8.51M
Capital expenditure$169,917$396,451
Free cash flow-$6.67M-$8.90M
Investing cash flow-$150,218-$359,216
Financing cash flow-$27,709$18.52M
Depreciation & amortization$287,961$267,382
Stock-based compensation$1.99M$1.13M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.